Escient launches to tackle itching and anaphylactoid drug targets
Wednesday, July 25, 2018 - 13:36
in Biology & Nature
The startup raised $40 million to target a class of GPCRs called Mas-related G-protein receptors, to treat neuroimmune and inflammatory conditions